Kimberly Strickland, MD
Medical Oncology · Charlotte, NCNPI 1376800698
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,125 of the $4,577 with a category attached, or 90.1%. AstraZeneca accounts for 91.4% of it on its own, with 6 other manufacturers making up the rest.
Across 13 payments — averaging $352.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Merck$168
- Gilead$109
- Genentech USA, Inc.$40
- Medtronic$39
- Novartis$20
- plus $15 from 1 others
Across 34 payments — averaging $32,147 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$490K
- AstraZeneca$420K
- Genentech, Inc.$122K
- Astrazeneca UK Limited$60K
What the payments were for
- Consulting fees$4,12590%
- Food & beverage$45210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $4,185 |
| Merck | 2 | $168 |
| Gilead | 2 | $109 |
| Genentech USA, Inc. | 2 | $40 |
| Medtronic | 1 | $39 |
| Novartis | 1 | $20 |
| Genentech, Inc. | 1 | $15 |
How this compares
$4,577 in reported general payments places this provider in the 65th percentile of 170 medical oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 18 | $260,665 |
| EliquisApixaban | 14 | $7,973 |
| Anastrozole | 264 | $5,133 |
| Exemestane | 17 | $1,942 |
| Letrozole | 72 | $1,318 |
| Tamoxifen Citrate | 80 | $1,316 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 14 | $189 |
| Ondansetron Hcl | 25 | $166 |
| Prochlorperazine Maleate | 17 | $157 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Charlotte
- David RizzieriCharlotte$714K
- Nilanjan GhoshCharlotte$510K
- Mohamed SalemCharlotte$396K
- Edward KimCharlotte$188K
- Kathryn MilehamCharlotte$110K
- Antoinette TanCharlotte$89K
- Jimmy HwangCharlotte$64K
- Ashley SumrallCharlotte$55K
- Obiageli OgbataCharlotte$26K
- Daniel CarrizosaCharlotte$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.